As a hearing on Trump administration’s federal marijuana rescheduling proposal proceeds this month, a new poll shows that most cannabis consumers aren’t optimistic that reform will be fully implemented by the end of the year.
Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III.
Under a separate order the acting attorney general signed, the ongoing hearing is considering more comprehensively moving marijuana to Schedule III—but the new survey, conducted by cannabis telehealth platform NuggMD, shows that most consumers don’t think that will happen by the time 2026 is over.
“In April, medical cannabis was partially rescheduled, moved to a less-restricted category,” the respondents were told. “Now, the federal government is weighing whether to extend that change to all other cannabis, which remained federally prohibited.”
“Do you think that will happen by the end of the year?” they were asked.
A majority—52.5 percent—said they do not think full cannabis rescheduling will happen by the end of the year, while 47.5 percent said they do expect to see the reform announced
Read full article on Marijuana Moment
